ArticleBMC cancer2024

Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.

Yinghao Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.